Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Kim J-, Yang Y-, Hong J, Chaugule S, Chun H, van der Meulen MC, et al. Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway. Elife. 2022;11.

Chen X, Du Y-. "RHAMM knockout" mice express a truncated RHAMM protein that promotes pancreatic cancer progression with dysfunctional p53. Ann Pancreat Cancer. 2022;5.

Butler-Laporte G, Gonzalez-Kozlova E, Su C-, Zhou S, Nakanishi T, Brunet-Ratnasingham E, et al. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. Clin Proteomics. 2022;19(1):34.

Brady NJ, Patel PS, Moayedi S, Sward D. A novel source of carbon monoxide for suicide attempt. Undersea Hyperb Med. 2022;49(3):329-331.

Taylor AS, Liu N, Fang JM, Panarelli N, Zhao L, Cheng J, et al. Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability. J Clin Pathol. 2022;75(7):483-487.

Feng H, Jiang B, Xing W, Sun J, Greenblatt MB, Zou W. Skeletal stem cells: origins, definitions, and functions in bone development and disease. Life Med. 2022;1(3):276-293.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Vougiouklakis T, Zhu K, Vasudevaraja V, Serrano J, Shen G, Linn RL, et al. Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements. Clin Cancer Res. 2022;28(8):1724-1733.

Church AJ, Corson LB, Kao P-, Imamovic-Tuco A, Reidy D, Doan D, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022;28(8):1581-1589.

Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219-229.